Sort
10,766 grants matching “checkpoint inhibitor”
Development of Physiologic Tissue Models to Assess Tumor Explant Response to Immune Checkpoint Blockade
$826,420Roger D. Kamm · Massachusetts Institute Of Technology · U01 · FY2021 · CA
Tumor Suppressor Protein, p53
$826,409Ettore Appella · Basic Sciences · Z01 · FY2007 · CA
AAV-delivered HIV inhibitors for SHIV therapy
$826,302Matthew Ryan Gardner · Emory University · R01 · FY2022 · DA
Immune epigenetic biomarkers of survival in glioma epidemiology
$825,775John K. Wiencke · University Of California, San Francisco · R01 · FY2017 · CA
PROJECT 1: TIME-Based Spatiotemporal Cancer Immunograms Predictive for Immunotherapy-Targeted Therapy Sequential Combinations
$825,019James R. Heath · Institute For Systems Biology · U54 · FY2022 · CA
Clinical evaluation of combination oncolytic viro-immunotherapy for solid tumors
$823,919Luke O. Russell · Vyriad, Inc. · R44 · FY2020 · CA
Examining IgG4 sialylation as a gain of function post-translation modification in IgG4-related diseases
$822,968Robert McCullough Anthony · Massachusetts General Hospital · R01 · FY2021 · AI
Examining IgG4 sialylation as a gain of function post-translation modification in IgG4-related diseases
$822,968Robert McCullough Anthony · Massachusetts General Hospital · R01 · FY2023 · AI
Examining IgG4 sialylation as a gain of function post-translation modification in IgG4-related diseases
$822,968Robert McCullough Anthony · Massachusetts General Hospital · R01 · FY2024 · AI
Examining IgG4 sialylation as a gain of function post-translation modification in IgG4-related diseases
$822,968Robert McCullough Anthony · Massachusetts General Hospital · R01 · FY2022 · AI
Advancing treatment and understanding of immunotherapy in glioblastoma
$821,970Nicholas A Butowski · University Of California, San Francisco · U19 · FY2023 · CA
Advancing treatment and understanding of immunotherapy in glioblastoma
$821,968Nicholas A Butowski · University Of California, San Francisco · U19 · FY2022 · CA
Therapeutic evaluation in ovarian and breast cancer GEM-GDA models
$821,958Shyam Sharan · Division Of Basic Sciences - Nci · ZIA · FY2021 · CA
Exploring Siglec-glycan ligand interactions using chemoenzymatic approaches
$821,772Peng Wu · Scripps Research Institute, The · R01 · FY2025 · AI
Immune epigenetic biomarkers of survival in glioma epidemiology
$821,594John K. Wiencke · University Of California, San Francisco · R01 · FY2019 · CA
Immunologic and Antigenic Drivers of Immune Checkpoint Inhibitor-Associated Myocarditis
$820,373Justin M Balko · Vanderbilt University Medical Center · R01 · FY2022 · HL
Enhancing Cancer Immunotherapy: Targeting the Tumor and Targeting the Host
$820,359Ronald Levy · Stanford University · R35 · FY2022 · CA
Molecular, Cellular, and Tissue Characterization Unit
$819,068Joe W. Gray · Oregon Health & Science University · U2C · FY2018 · CA
Strategies for Therapeutic Cancer Vaccine Clinical Trials
$816,925Jeffrey Schlom · Division Of Basic Sciences - Nci · ZIA · FY2012 · CA
A Multi-Institute Survivorship Study of Patients Living with Advanced Cancer Who Have Had Durable Response to Immune Checkpoint Inhibitors
$815,928Song Yao · Roswell Park Cancer Institute Corp · R01 · FY2023 · CA
Immunologic and Antigenic Drivers of Immune Checkpoint Inhibitor-Associated Myocarditis
$815,509Justin M Balko · Vanderbilt University Medical Center · R01 · FY2023 · HL
Determinants of response to cancer immunotherapy
$815,497Lawrence Fong · University Of California, San Francisco · R35 · FY2021 · CA
Exploring Siglec-glycan ligand interactions using chemoenzymatic approaches
$815,317Peng Wu · Scripps Research Institute, The · R01 · FY2021 · AI
Epigenetic Therapy for Thoracic Malignancies
$813,216David Schrump · Division Of Clinical Sciences - Nci · ZIA · FY2019 · CA
The role of the CD58:CD2 axis in cancer immune evasion and resistance to immunotherapy
$812,586Christopher Frangieh · Columbia University Health Sciences · R01 · FY2025 · CA